Last reviewed · How we verify

Placebo of DA-2803-R

Dong-A ST Co., Ltd. · FDA-approved active Small molecule

Placebo of DA-2803-R is a Small molecule drug developed by Dong-A ST Co., Ltd.. It is currently FDA-approved.

A placebo formulation containing no active pharmaceutical ingredient, used as a control in clinical trials.

At a glance

Generic namePlacebo of DA-2803-R
SponsorDong-A ST Co., Ltd.
ModalitySmall molecule
PhaseFDA-approved

Mechanism of action

Placebo products are inert formulations designed to match the appearance and administration route of an active drug while containing no therapeutic agent. They are used in randomized controlled trials to establish the true efficacy of an investigational drug by comparing outcomes against a non-treatment control. The placebo effect itself may produce measurable but non-pharmacological improvements in patient-reported outcomes.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo of DA-2803-R

What is Placebo of DA-2803-R?

Placebo of DA-2803-R is a Small molecule drug developed by Dong-A ST Co., Ltd..

How does Placebo of DA-2803-R work?

A placebo formulation containing no active pharmaceutical ingredient, used as a control in clinical trials.

Who makes Placebo of DA-2803-R?

Placebo of DA-2803-R is developed and marketed by Dong-A ST Co., Ltd. (see full Dong-A ST Co., Ltd. pipeline at /company/dong-a-st-co-ltd).

What development phase is Placebo of DA-2803-R in?

Placebo of DA-2803-R is FDA-approved (marketed).

Related